Experimental immune cell therapy for liver cancer hits early roadblock

NCT ID NCT04502082

Terminated Disease control Sponsor: Eureka Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial tested a new type of immune cell therapy (ET140203 T cells) in 8 adults with advanced liver cancer that had not responded to other treatments. The therapy was designed to target a protein called AFP found on cancer cells. The study was terminated early, so we have very limited information on safety or effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: engineered immune cells (ET140203 T cells)
What this could lead to: If this approach had worked, it could have pointed toward a new treatment option for people with advanced liver cancer who have run out of standard therapies.
What could go wrong: This was a very early, small trial that was terminated before completion. The therapy may not be effective or safe enough, and it is unclear if it will ever be tested further.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma liver and intrahepatic bile duct neoplasm liver cancer Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA LIVER CANCER LIVER NEOPLASM METASTATIC LIVER CANCER

Contacts and locations

Locations

City of Hope Medical Center

Duarte, California, 91010, United States
Kansas University Medical Center

Westwood, Kansas, 66205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.